Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Dendreon (Nasdaq: DNDN ) has received a distressing two-star ranking.
With that in mind, let's take a closer look at Dendreon's business and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||Seattle (1992)|
|Market Cap||$682.6 million|
|Trailing-12-Month Revenue||$428.5 million|
|Management||Chairman/CEO John Johnson
CFO Gregory Schiffman
|Return on Capital (average, past 3 years)||(23%)|
|Cash/Debt||$432.2 million / $578.8 million|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 17% of the 1,613 members who have rated Dendreon believe the stock will underperform the S&P 500 going forward.
This past summer, one of those Fools, NHWeston102, succinctly summed up the bear case for our community: "Dendreon appears rudderless. They are firing sales people, honking off physicians, and their [prostate cancer drug Provenge] is just too expensive. Others are breaching their moat. Not looking good."
If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.